Cargando…
Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?
Severe refractory asthma is characterized by a higher risk of asthma-related symptoms, morbidities, and exacerbations. This disease also determines much greater healthcare costs and deterioration in health-related quality of life (HR-QoL). Another concern, which is currently much discussed, is the h...
Autores principales: | Menzella, Francesco, Biava, Mirella, Bagnasco, Diego, Galeone, Carla, Simonazzi, Anna, Ruggiero, Patrizia, Facciolongo, Nicola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469746/ https://www.ncbi.nlm.nih.gov/pubmed/31024635 http://dx.doi.org/10.7573/dic.212580 |
Ejemplares similares
-
Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021) -
Real world effectiveness of benralizumab on respiratory function and asthma control
por: Menzella, Francesco, et al.
Publicado: (2021) -
The clinical profile of benralizumab in the management of severe
eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016) -
Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty
por: Menzella, Francesco, et al.
Publicado: (2017) -
A case of chronic eosinophilic pneumonia in a patient treated with dupilumab
por: Menzella, Francesco, et al.
Publicado: (2019)